Alzheimer's disease

Korean Healthtech Startup Closing In On Cure For Alzheimer's
Forbes
Tue, 06/30/15 - 10:47 am
Korea
Alzheimer's disease
Ybrain
wearables
devices
Lilly's Alzheimer's Game
Seeking Alpha
Sun, 06/28/15 - 11:32 am
Eli Lilly
Alzheimer's disease
solanezumab
Deep in ‘the Cave,' Lilly's CEO Decided Alzheimer's Drug's Fate
Yahoo/Bloomberg
Fri, 06/26/15 - 11:45 am
Eli Lilly
Alzheimer's disease
John Lechleiter
3 Reasons That Biogen's Shares Could Rise
Investopedia
Wed, 06/17/15 - 10:05 am
Biogen
Alprolix
Eloctate
hemophilia A
hemophilia B
aducanumab
Alzheimer's disease
What You May Have Missed in Biotech: Cholesterol Drug Scrutiny and a Hedge Fund Alzheimer's Play
Forbes
Sat, 06/13/15 - 10:36 am
biotech
GSK
Axovant Sciences
Alzheimer's disease
PCSK9 inhibitors
Praluent
Sanofi
Regeneron
Repatha
Amgen
Biogen's CEO Spending Spree Comes At The Expense Of Shareholders
Seeking Alpha
Sat, 06/13/15 - 09:38 am
George Scangos
Biogen
Alzheimer's disease
aducanumab
Is Excitement Over Eli Lilly’s Alzheimer’s Drug Overdone?
Barron's
Fri, 06/12/15 - 10:50 pm
Eli Lilly
Alzheimer's disease
solanezumab
Lilly shares sizzle as investors await Alzheimer's data
Yahoo/Reuters
Fri, 06/12/15 - 09:33 am
Eli Lilly
Alzheimer's disease
solanezumab
Roche Takes Another Shot at Alzheimer’s After Biogen Success
Bloomberg
Tue, 06/9/15 - 10:20 am
Roche
Biogen
Alzheimer's disease
gantenerumab
The legal death of Actavis' Namenda strategy spells doom for the 'hard switch'
Fierce Pharma
Tue, 05/26/15 - 10:53 am
Actavis
Namenda
generics
hard switch
Alzheimer's disease
Upcoming Events: A Dosing Decision For BioMarin, Plus Roche To Get Alzheimer's Data
Seeking Alpha
Mon, 05/25/15 - 12:41 pm
Biomarin
Roche
Alzheimer's disease
RG1577
Actavis Must Keep its Older Alzheimer’s Pill on the Market
WSJ Pharmalot
Fri, 05/22/15 - 06:23 pm
Actavis
Alzheimer's disease
hard switch
Namenda XR
No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon
Fierce Pharma Marketing
Mon, 05/18/15 - 11:32 am
Actavis
Namenda
hard switch
Namenda XR
Namzaric
Alzheimer's disease
That Namenda hard switch Actavis wants? It could cost HHS $6B
Fierce Pharma Marketing
Tue, 05/12/15 - 08:10 am
Namenda XR
Alzheimer's disease
Actavis
HHS
hard switch
Actavis and its Forced Switch Could Cost Medicare $288M This Year: Study
WSJ Pharmalot
Thu, 05/7/15 - 11:06 am
Actavis
Namenda XR
Alzheimer's disease
Medicare
Biogen to Spend $2.5 Billion Before Alzheimer’s Drug Results
Bloomberg
Tue, 04/28/15 - 09:50 am
Biogen
Alzheimer's disease
BIIB037
Roche's $100M Alzheimer's study could shift the balance in R&D
Fierce Biotech
Mon, 04/27/15 - 09:16 pm
Roche
Alzheimer's disease
R&D
Biogen blueprints a big Phase III effort for its Alzheimer's hopeful
Fierce Biotech
Fri, 04/24/15 - 11:22 am
Biogen
Alzheimer's disease
aducanumab
Roche more confident in beating Alzheimer's after Biogen data
Yahoo/Reuters
Wed, 04/22/15 - 10:12 am
Roche
Alzheimer's disease
Biogen
gantenerumab
crenezumab
Actavis Wins a ‘Product Hopping’ Case as Namenda Battle Rages On
WSJ Pharmalot
Tue, 04/21/15 - 01:34 pm
Actavis
Namenda
Namenda XR
hard switch
Alzheimer's disease

Pages